Clinical Trial Update: The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the impact of dupilumab on quality of life in adults with moderate-to-severe atopic dermatitis. Completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Status: COMPLETED | Results posted: 2024-01-09